Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.20084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[A circuitous route to the diagnosis of a very rare disease].
Inn Med (Heidelb)
August 2025
Abteilung für Innere Medizin, Kreisklinik Trostberg, Siegerthöhe 1, 83308, Trostberg, Deutschland.
This case of a patient with Erdheim-Chester disease highlights the problems in diagnosing this very rare, largely unknown, but highly inflammatory non-Langerhans histiocytosis. This disease shows some characteristic clinical and molecular features including the BRAF V600E mutation, which was also demonstrated in this case in a perirenal tissue biopsy. The patient's condition improved under treatment with peginterferon alfa-2a and anakinra.
View Article and Find Full Text PDFComparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta-Analysis.
Liver Int
August 2025
Department of Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
Background And Aims: Treatment of chronic hepatitis delta virus (HDV) infection with pegylated interferon-alpha (PEG-IFN-alpha) is associated with variable and often poor treatment responses. Recently, bulevirtide was approved for chronic HDV infection with promising results.
Methods: We conducted a pairwise network meta-analysis of five treatment regimens-bulevirtide, bulevirtide plus PEG-IFN-alpha, PEG-IFN-alpha, lonafarnib and lonafarnib plus PEG-IFN-alpha-by reviewing randomised studies in PubMed, EMBASE and Web of Science.
A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.
Ann Hematol
July 2025
Levine Cancer Institute, Cancer Programs, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, USA.
Cytoreductive therapies remain vital to the management of polycythemia vera (PV). Real-world data are needed to complement clinical trial safety information. We evaluated the safety profiles of four commonly used PV therapies—ropeginterferon alfa-2b (ropeg, on-label), peginterferon alfa-2a (peg-IFN, off-label), ruxolitinib (on-label), and hydroxyurea (HU, off-label)—using the FDA Adverse Event Reporting System (FAERS) database.
View Article and Find Full Text PDFClinical outcomes after HBsAg clearance in chronic hepatitis B patients treated with Peg-IFN α: A study with an 11- to 173-month follow-up.
Virol Sin
August 2025
Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China; HBV Infection, Clinical Cure and Immunology Joint Laboratory, Capital Medical University, Beijing, 100069, China; Department of Hepatology Division 2, Peking University Ditan Teaching Hos
To investigate the risk and influencing factors of long-term liver adverse events in chronic hepatitis B patients achieving hepatitis B surface antigen (HBsAg) clearance after pegylated interferon α (Peg-IFN α) treatment, a retrospective analysis was conducted on 456 patients at Beijing Ditan Hospital from 2008 to 2023 who achieved HBsAg clearance and discontinued Peg-IFN α treatment. The baseline was defined as the time of HBsAg clearance and treatment cessation. The endpoint was the first occurrence of liver adverse events (hepatocellular carcinoma or ascites) or last follow-up.
View Article and Find Full Text PDF